Cargando…
Overexpression of SphK2 contributes to ATRA resistance in colon cancer through rapid degradation of cytoplasmic RXRα by K48/K63-linked polyubiquitination
The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that is mainly located in the nucleus and endoplasmic reticulum. Unlike well-studied sphingosine kinase 1 (SphK1) located in the cytosol, l...
Autores principales: | Shi, Wen-Na, Cui, Shu-Xiang, Song, Zhi-Yu, Wang, Shu-Qing, Sun, Shi-Yue, Yu, Xin-Feng, Li, Ye, Zhang, Yu-Hang, Gao, Zu-Hua, Qu, Xian-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503636/ https://www.ncbi.nlm.nih.gov/pubmed/28465486 http://dx.doi.org/10.18632/oncotarget.17174 |
Ejemplares similares
-
Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget
por: Hatoum, Diana, et al.
Publicado: (2017) -
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
por: Bu, Yanhong, et al.
Publicado: (2021) -
Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk
por: Schiefler, Carlotta, et al.
Publicado: (2014) -
Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
por: Shi, Weiwei, et al.
Publicado: (2020) -
SphK2 over-expression promotes osteosarcoma cell growth
por: Xu, Dawei, et al.
Publicado: (2017)